Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/KANSL1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/KANSL1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/KANSL1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/KANSL1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/KANSL1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/KANSL1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/KANSL1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/KANSL1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/KANSL1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/KANSL1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/KANSL1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000647311 | Prostate | Tumor | protein acetylation | 59/3246 | 201/18723 | 1.68e-05 | 2.25e-04 | 59 |
GO:004354311 | Prostate | Tumor | protein acylation | 63/3246 | 243/18723 | 4.64e-04 | 3.48e-03 | 63 |
GO:001657311 | Prostate | Tumor | histone acetylation | 43/3246 | 152/18723 | 5.27e-04 | 3.85e-03 | 43 |
GO:001839311 | Prostate | Tumor | internal peptidyl-lysine acetylation | 44/3246 | 158/18723 | 6.58e-04 | 4.66e-03 | 44 |
GO:000647511 | Prostate | Tumor | internal protein amino acid acetylation | 44/3246 | 160/18723 | 8.75e-04 | 5.87e-03 | 44 |
GO:00165709 | Skin | AK | histone modification | 84/1910 | 463/18723 | 1.10e-07 | 4.95e-06 | 84 |
GO:00182058 | Skin | AK | peptidyl-lysine modification | 66/1910 | 376/18723 | 7.80e-06 | 1.72e-04 | 66 |
GO:00064736 | Skin | AK | protein acetylation | 39/1910 | 201/18723 | 6.08e-05 | 9.02e-04 | 39 |
GO:00183946 | Skin | AK | peptidyl-lysine acetylation | 32/1910 | 169/18723 | 4.20e-04 | 4.00e-03 | 32 |
GO:00435436 | Skin | AK | protein acylation | 42/1910 | 243/18723 | 4.59e-04 | 4.28e-03 | 42 |
GO:00183936 | Skin | AK | internal peptidyl-lysine acetylation | 29/1910 | 158/18723 | 1.27e-03 | 9.63e-03 | 29 |
GO:00165736 | Skin | AK | histone acetylation | 28/1910 | 152/18723 | 1.44e-03 | 1.06e-02 | 28 |
GO:00064756 | Skin | AK | internal protein amino acid acetylation | 29/1910 | 160/18723 | 1.55e-03 | 1.12e-02 | 29 |
GO:001657016 | Skin | SCCIS | histone modification | 37/919 | 463/18723 | 2.53e-03 | 2.44e-02 | 37 |
GO:001657024 | Skin | cSCC | histone modification | 179/4864 | 463/18723 | 9.65e-10 | 3.74e-08 | 179 |
GO:000647314 | Skin | cSCC | protein acetylation | 84/4864 | 201/18723 | 6.94e-07 | 1.29e-05 | 84 |
GO:001839414 | Skin | cSCC | peptidyl-lysine acetylation | 72/4864 | 169/18723 | 1.81e-06 | 3.02e-05 | 72 |
GO:001820515 | Skin | cSCC | peptidyl-lysine modification | 137/4864 | 376/18723 | 4.09e-06 | 6.09e-05 | 137 |
GO:004354314 | Skin | cSCC | protein acylation | 95/4864 | 243/18723 | 4.56e-06 | 6.71e-05 | 95 |
GO:000647514 | Skin | cSCC | internal protein amino acid acetylation | 66/4864 | 160/18723 | 1.72e-05 | 2.07e-04 | 66 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
KANSL1 | SNV | Missense_Mutation | rs369793673 | c.103N>A | p.Glu35Lys | p.E35K | Q7Z3B3 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
KANSL1 | SNV | Missense_Mutation | novel | c.1527N>A | p.Asp509Glu | p.D509E | Q7Z3B3 | protein_coding | tolerated(0.62) | benign(0.017) | TCGA-BH-A18L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
KANSL1 | SNV | Missense_Mutation | rs779806189 | c.2660C>T | p.Thr887Met | p.T887M | Q7Z3B3 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-OL-A6VQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KANSL1 | SNV | Missense_Mutation | novel | c.2358N>A | p.Met786Ile | p.M786I | Q7Z3B3 | protein_coding | deleterious(0.03) | benign(0.037) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
KANSL1 | insertion | In_Frame_Ins | novel | c.3091_3092insGGAGATATATGGAACTAGTGGAGATATATGGAA | p.Ser1031delinsTrpArgTyrMetGluLeuValGluIleTyrGlyThr | p.S1031delinsWRYMELVEIYGT | Q7Z3B3 | protein_coding | | | TCGA-A8-A07G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR |
KANSL1 | deletion | Frame_Shift_Del | | c.2902delN | p.Gln968SerfsTer46 | p.Q968Sfs*46 | Q7Z3B3 | protein_coding | | | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
KANSL1 | insertion | Frame_Shift_Ins | novel | c.2277_2278insAACCAGTTTTATTCTCATCACCTGCTCTCTATCTCTGGCTCTAAAT | p.Val760AsnfsTer36 | p.V760Nfs*36 | Q7Z3B3 | protein_coding | | | TCGA-AN-A0FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KANSL1 | deletion | Frame_Shift_Del | novel | c.1710delN | p.Gln570HisfsTer8 | p.Q570Hfs*8 | Q7Z3B3 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
KANSL1 | SNV | Missense_Mutation | novel | c.2201N>T | p.Ala734Val | p.A734V | Q7Z3B3 | protein_coding | tolerated(0.27) | benign(0.148) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
KANSL1 | SNV | Missense_Mutation | rs775472991 | c.31N>A | p.Ala11Thr | p.A11T | Q7Z3B3 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |